Page last updated: 2024-12-07

desmethylsertraline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Desmethylsertraline is a major metabolite of the antidepressant sertraline. It is formed by the removal of a methyl group from the sertraline molecule. Desmethylsertraline has been shown to have antidepressant activity in animal models, but it is not currently marketed as a drug. It is often studied as a potential therapeutic target for depression and other mental health conditions. Research into desmethylsertraline aims to understand its pharmacological properties and potential therapeutic applications.'

desmethylsertraline: metabolite of sertraline [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID114743
CHEMBL ID40733
CHEMBL ID1743864
SCHEMBL ID145234
MeSH IDM0179249

Synonyms (32)

Synonym
PDSP2_001789
norsertraline
87857-41-8
desmethylsertraline
CHEMBL40733 ,
(1s,4s)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-amine
bdbm50028066
4-(3,4-dichloro-phenyl)-1,2,3,4-tetrahydro-naphthalen-1-ylamine, hcl
CHEMBL1743864 ,
cp-53261
demethylsertraline
n-demethylsertraline
cp 62508
n-desmethylsertraline
unii-cjj71o9be8
cjj71o9be8 ,
1-naphthalenamine, 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-, (1s-cis)-
bdbm50367182
1-naphthalenamine, 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-, (1s,4s)-
cis-(+/-)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine
SCHEMBL145234
SRPXSILJHWNFMK-ZBEGNZNMSA-N
DTXSID60236666
mfcd00871799
(1s,4s)-4-(3,4-dichloro-phenyl)-1,2,3,4-tetrahydronaphthalen-1-amine
AKOS027382323
(1s-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine
rel-(1r,4r)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine
DTXSID60904333
Q5264613
DB14071
BS-38512

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"A nonblinded study was conducted to compare the pharmacokinetic properties of the selective serotonin reuptake inhibitor sertraline in 22 young (aged 18 to 45 years) and 22 elderly (> 65 years) volunteers, of whom half were male and half were female."( Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers.
Ronfeld, RA; Tremaine, LM; Wilner, KD, 1997
)
0.3
"05) and terminal elimination half-life values of sertraline (35."( Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19.
Chen, XP; He, N; Liu, ZQ; Shu, Y; Wang, JH; Wang, W; Zhou, HH, 2001
)
0.31
" The present study reports the pharmacokinetic results of up to eight serum samples per patient."( Serum disposition of sertraline, N-desmethylsertraline and paroxetine: a pharmacokinetic evaluation of repeated drug concentration measurements during 6 months of treatment for major depression.
Aberg-Wistedt, A; Agren, H; Akerblad, AC; Bengtsson, F; Höglund, P; Reis, M, 2004
)
0.6
" For each sampling period for SER, area under the serum concentration versus time curve, maximal serum concentration (Cmax), and the time at which Cmax occurred (Tmax) were determined."( Pharmacokinetics of sertraline across pregnancy and postpartum.
Anthony, M; Davis, MF; Fankhauser, M; Freeman, MP; Fried, K; Moreno, F; Nolan, PE; Woosley, RL, 2008
)
0.35
"Sertraline is one of the most prescribed antidepressants, but its pharmacokinetic (PK) properties are still not completely characterized."( Population Pharmacokinetic Modeling to Inform Sertraline Dosing Optimization in Patients with Depression.
Ilic, N; Jankovic, SM; Milovanovic, J; Nikolic, VN; Popovic, D; Stoiljkovic, M; Vujovic, M, 2023
)
0.91

Dosage Studied

ExcerptRelevanceReference
" In this study, sertraline was administered at a dosage of 200mg once daily (the maximum recommended daily dosage) for 21 days after upward dosage titration from 50 mg/day over a 9-day period."( Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers.
Ronfeld, RA; Tremaine, LM; Wilner, KD, 1997
)
0.3
"6 kg, and their mean sertraline dosage was 55 mg/d."( The effects of grapefruit juice on sertraline metabolism: an in vitro and in vivo study.
Buffum, J; Bui, BC; Chan, WK; Harralson, AF; Lee, AJ, 1999
)
0.3
"Insufficient data inform dosing of antidepressants and clinical monitoring for major depressive disorder (MDD) during the perinatal period."( Pharmacokinetics of sertraline across pregnancy and postpartum.
Anthony, M; Davis, MF; Fankhauser, M; Freeman, MP; Fried, K; Moreno, F; Nolan, PE; Woosley, RL, 2008
)
0.35
" Monitoring the body levels of this drug and its active metabolite, N-desmethylsertraline (DSRT), permits optimizing the dosage and personalizing the treatment, especially in the case of severe adverse reactions or lack of response to the applied therapy."( Sertraline - isolation methods and quantitation in biological material.
Dziurkowska, E; Wesolowski, M, 2018
)
0.71
" This finding can serve to inform sertraline dosing optimization, especially when changes in kidney function occur in treated individuals, to prevent adverse drug reactions and maximize therapeutic benefits."( Population Pharmacokinetic Modeling to Inform Sertraline Dosing Optimization in Patients with Depression.
Ilic, N; Jankovic, SM; Milovanovic, J; Nikolic, VN; Popovic, D; Stoiljkovic, M; Vujovic, M, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID681144TP_TRANSPORTER: cell accumulation of calcein in L-MDR1 cells2003The Journal of pharmacology and experimental therapeutics, Apr, Volume: 305, Issue:1
Inhibition of P-glycoprotein by newer antidepressants.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (52)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's20 (38.46)18.2507
2000's22 (42.31)29.6817
2010's5 (9.62)24.3611
2020's5 (9.62)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 37.57

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index37.57 (24.57)
Research Supply Index4.17 (2.92)
Research Growth Index4.71 (4.65)
Search Engine Demand Index50.99 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (37.57)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials8 (14.29%)5.53%
Reviews1 (1.79%)6.00%
Case Studies5 (8.93%)4.05%
Observational1 (1.79%)0.25%
Other41 (73.21%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]